| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-031 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 第五届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事会会议召开情况 塞力斯医疗科技集团股份有限公司(以下简称"公司"）2025 年 4 月 17 日 以邮件方式发送第五届董事会第十四次会议通知，会议于 2025 年 4 月 27 日在公 司 A 栋 C 会议室以现场和通讯相结合的方式召开。本次会议应到董事 8 人，实到 董事 8 人，会议由董事长温伟先生主持，公司全体监事和高级管理人员列席了会 议。 本次董事会经过了适当的通知程序，会议的召集、召开和表决程序符合《公 司法》等相关法律法规和《公司章程》的规定，会议及通过的决议合法有效。 二、董事会会议审议情况 本次会议审议并通过如下议案： （一）审议通过《关于 2024 年度总经理工作报告的议案》 表决结果： ...

重要内容提示： 截至2025年4月28日，塞力斯医疗科技集团股份有限公司（以下简称"公 司"）已触发"塞力转债"向下修正条款。 经第五届董事会第十五次会议审议通过，公司董事会决定本次不向下修 正"塞力转债"转股价格。 下一触发转股价格修正条件的期间从2025年4月29日开始重新起算，若再 次触发"塞力转债"的转股价格向下修正条款，届时公司董事会将召开会议决定 是否行使"塞力转债"的转股价格向下修正的权利。 一、可转换公司债券基本情况 | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-038 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于不向下修正"塞力转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一）可转换公司债券发行情况 经中国证券监督管理委员会（证监许可【2020】1033号）核准，公司于2020 年8月21日公开发行了543.31万张可转换公司债券，每张面值100元，发行总额 ...

塞力斯医疗科技集团股份有限公司 2024 年度独立董事述职报告 本人刘炜，作为塞力斯医疗科技集团股份有限公司（以下简称"公司"）的 独立董事，任职期间我严格按照《中华人民共和国公司法》《上市公司治理准则》 《上海证券交易所上市公司自律监管指引第1号——规范运作》《上市公司独立 董事管理办法》等法律法规及《公司章程》《独立董事工作制度》的相关规定， 勤勉、尽责、忠实履行职务，积极出席相关会议，认真审议董事会的各项议案并 对相关事项发表独立意见，维护了公司和股东，特别是中小股东的合法权益。 报告期内，我因连续担任公司独立董事满六年，根据《上市公司独立董事管 理办法》等相关规定，我自2024年8月12日起不再担任公司独立董事及各专门委 员会委员职务。现就2024年度任职期间履职情况报告如下： 一、独立董事的基本情况 刘炜，中国国籍，无境外永久居留权，1972年出生，中国人民大学博士后， 中国国民党革命委员会党员，湖北省会计领军人才。历任科技部管理学院见习研 究员、教师，科技部条财司财务处科员，华中科技大学教师、EDP中心主任、院 长助理、EMBA中心主任，中国人民大学金融证券研究所研究员。刘炜女士于2016 年4月 ...

塞力斯医疗科技集团股份有限公司 2024 年度独立董事述职报告 本人施先旺，自2024年8月12日起担任塞力斯医疗科技集团股份有限公司（以 下简称"公司"）的第五届董事会独立董事，本人严格按照《中华人民共和国公 司法》《上市公司治理准则》《上海证券交易所上市公司自律监管指引第1号— —规范运作》《上市公司独立董事管理办法》等法律法规及《公司章程》《独立 董事工作制度》的相关规定，在2024年度任职期间内，勤勉、尽责、忠实履行职 务，积极出席相关会议，认真审议董事会的各项议案并对相关事项发表独立意见， 维护了公司和股东，特别是中小股东的合法权益。现将2024年度履行职责情况汇 报如下： 一、独立董事的基本情况 施先旺，中国国籍，无境外永久居留权，1968年生，管理学博士，教授、博 士生导师。主要研究领域为会计基本理论，具体包括资金运动会计、会计与信息 技术发展、业财合一、会计与资本市场等。在《会计研究》、《审计研究》等期 刊发表论文数十篇。主持和参与国家社科项目、国家自科项目多项，主持省部级 项目多项。曾任武汉金运激光股份有限公司、葵花药业集团股份有限公司独立董 事，现任中南财经政法大学教师，武汉明德生物科技股 ...

塞力斯医疗科技集团股份有限公司 2024 年度独立董事述职报告 本人张兆国，自2024年8月12日起担任塞力斯医疗科技集团股份有限公司（以 下简称"公司"）的第五届董事会独立董事，本人严格按照《中华人民共和国公 司法》《上市公司治理准则》《上海证券交易所上市公司自律监管指引第1号— —规范运作》《上市公司独立董事管理办法》等法律法规及《公司章程》《独立 董事工作制度》的相关规定，在2024年度任职期间内，勤勉、尽责、忠实履行职 务，积极出席相关会议，认真审议董事会的各项议案并对相关事项发表独立意见， 维护了公司和股东，特别是中小股东的合法权益。 现将本人2024年度（8-12月）履行职责情况汇报如下： 一、独立董事的基本情况 张兆国，中国国籍,无境外永久居留权,1956年出生,华中科技大学管理学院 会计系主任、教授、博士生导师。现兼任武汉工商学院管理学院院长、湖北省会 计学会副会长、中国会计学会高等工科院校分会副会长等职。2024年8月起任公 司独立董事。 作为公司独立董事，本人未在公司担任除董事以外的其他职务，与公司、公 司的控股股东及其关联方不存在可能妨碍本人进行独立客观判断的关系，本人也 没有从公司、公 ...

塞力斯医疗科技集团股份有限公司 2024 年度独立董事述职报告 本人张开华，作为塞力斯医疗科技集团股份有限公司（以下简称"公司"） 的独立董事，我严格按照《中华人民共和国公司法》《上市公司治理准则》《上 海证券交易所上市公司自律监管指引第1号——规范运作》《上市公司独立董事 管理办法》等法律法规及《公司章程》《独立董事工作制度》的相关规定，在2024 年度工作中，勤勉、尽责、忠实履行职务，积极出席相关会议，认真审议董事会 的各项议案并对相关事项发表独立意见，维护了公司和股东，特别是中小股东的 合法权益。 报告期内，我因连续担任公司独立董事满六年，根据《上市公司独立董事管 理办法》等相关规定，我自2024年8月12日起不再担任公司独立董事及各专门委 员会委员职务。现就2024年度任职期间履职情况报告如下： 一、独立董事的基本情况 张开华，中国国籍，无境外永久居留权，1962年出生，博士研究生学历，于 2009年至2012年受聘为湖北省委政策咨询顾问，2012年至2014年受聘为湖北省三 农研究院特约研究员，2014年至2016年受聘为湖北省委财办特约研究员，2015 年至2016年任大冶有色金属有限公司独立董事 ...

塞力斯医疗科技集团股份有限公司 一、独立董事的基本情况 张震，中国国籍，1974 年 1 月出生，无境外永久居留权，硕士，历任中国 高科集团股份有限公司投资经理、上海第一食品投资管理有限公司总裁助理、上 海万业企业股份有限公司投资主管、上海绿庭投资集团股份有限公司战略发展总 监、传化控股集团副总裁和上海境泽股权投资管理有限公司管理合伙人。现任深 圳天启泽瑞股权投资管理有限公司执行董事、上海春风物流股份有限公司和上海 春风来供应链管理有限公司董事长，兼任上海天引物流科技有限公司和杭州顽客 传媒有限公司执行董事、上海联九投资有限公司董事，2024 年 4 月至今任公司 独立董事。 作为公司独立董事，本人未在公司担任除董事以外的其他职务，与公司、公 司的控股股东及其关联方不存在可能妨碍本人进行独立客观判断的关系，本人也 没有从公司、公司控股股东及其关联方取得额外的、未予披露的其他利益。因此， 不存在影响独立性的情况。 二、独立董事年度履职概况 2024 年度独立董事述职报告 本人张震，自2024年4月26日起担任塞力斯医疗科技集团股份有限公司（以 下简称"公司"）的独立董事，本人严格按照《中华人民共和国公司法》《上 ...

塞力斯医疗科技集团股份有限公司 （二）出席董事会各专门委员会、独立董事专门会议工作情况 2024 年度独立董事述职报告 本人姚江，作为塞力斯医疗科技集团股份有限公司（以下简称"公司"）的 独立董事，我严格按照《中华人民共和国公司法》《上市公司治理准则》《上海 证券交易所上市公司自律监管指引第1号——规范运作》《上市公司独立董事管 理办法》等法律法规及《公司章程》《独立董事工作制度》的相关规定，在2024 年度工作中，勤勉、尽责、忠实履行职务，积极出席相关会议，认真审议董事会 的各项议案并对相关事项发表独立意见，维护了公司和股东，特别是中小股东的 合法权益。我已于2024年4月26日离任，现将我任职内履行职责情况汇报如下： 一、独立董事的基本情况 姚江，中国国籍，1967 年 8 月出生，中共党员，硕士研究生学历，金融类 经济师，高级经济师，注册风险管理师。曾参与筹建长江证券有限责任公司，先 后在营业部、发行部、基金部、投资银行部、资金部等核心业务岗位任经理；曾 在中国人民银行武汉分行（国家外汇管理局武汉分局）综合管理处、进出口核销 处、国际收支处等岗位从事监管工作；2016 年 5 月至 2017 年 8 月 ...

Financial Performance - The net profit attributable to shareholders of the listed company for 2024 is negative, leading to no cash dividends or capital reserve transfers for the year[6]. - The company's operating revenue for 2024 was approximately ¥1.81 billion, a decrease of 9.74% compared to ¥2.01 billion in 2023[26]. - The net profit attributable to shareholders for 2024 was approximately -¥209.24 million, representing a decline of 31.95% from -¥158.57 million in 2023[26]. - The cash flow from operating activities for 2024 was approximately ¥99.60 million, down 20.88% from ¥125.89 million in 2023[26]. - Total assets at the end of 2024 were approximately ¥2.83 billion, a decrease of 15.31% from ¥3.34 billion at the end of 2023[26]. - The net assets attributable to shareholders decreased by 22.84% to approximately ¥934.29 million in 2024 from ¥1.21 billion in 2023[26]. - The company reported a decrease in revenue from non-core business activities, with a total of approximately ¥1.81 billion in 2024, down 9.34% from ¥1.99 billion in 2023[26]. - The company recognized goodwill impairment losses totaling 25.22 million yuan across several subsidiaries, impacting overall financial performance[28]. - The company reported a net cash flow from operating activities of -27.15 million yuan in the first quarter of 2024, indicating cash flow challenges[33]. - Non-recurring losses amounted to 73.45 million yuan in 2024, compared to a loss of 11.71 million yuan in 2023[35]. Audit and Governance - The company has received a standard unqualified audit report from Zhongzheng Zhonghuan Accounting Firm[5]. - The board of directors has confirmed that all members attended the board meeting, ensuring accountability for the report's accuracy[4]. - The company has committed to maintaining the integrity and accuracy of its financial reports[5]. - The annual report is subject to approval at the 2024 annual general meeting of shareholders[6]. - The company has not reported any significant differences in governance compared to regulatory requirements[146]. - The company has not faced any major changes in competition or business independence issues from its controlling shareholders[146]. - The company is committed to optimizing governance and enhancing compliance awareness among its board and management team[170]. - The company implemented a registration management system for insider information to enhance transparency and protect shareholders' rights[146]. - The company held multiple shareholder meetings in 2024, including the first on January 15, where two proposals were approved, and the second on April 26, approving two additional proposals[146]. Strategic Development and Innovation - The company is focusing on the development of innovative technologies such as the TriVerity acute infection detection system and the LeviCell® cell separation technology[25]. - The company aims to expand its market presence through strategic partnerships and collaborations in the healthcare sector[25]. - The company is committed to enhancing its product offerings in molecular diagnostics and gut microbiome management[25]. - The company plans to continue its research and development efforts to improve diagnostic accuracy and patient outcomes[25]. - R&D investment in innovative technologies and software increased significantly, focusing on overseas technology commercialization and in vitro diagnostic reagent development[28]. - The company is actively transitioning from traditional IVD business to a light asset operation model, reducing fixed asset investments[43]. - The company is collaborating with Huawei to develop customized software solutions that meet hospitals' needs for flexible and low-cost solutions[45]. - The company is leveraging AI technology to optimize resource allocation and improve operational efficiency in healthcare institutions through various intelligent applications[66]. - The company aims to create a self-controlled, technology-leading innovative smart medical ecosystem by integrating AI and big data into its core business operations[64]. Market Trends and Opportunities - The aging population in China is projected to exceed 20% by 2030, driving increased demand for medical resources and healthcare spending[49]. - In 2024, the Chinese medical device market is expected to reach approximately 2.4 trillion yuan, with a compound annual growth rate (CAGR) of 16% by 2029[50]. - The SPD industry in China is projected to grow rapidly, with a market size of 64.2 billion yuan in 2024, of which the digital segment accounts for 19.3 billion yuan, reflecting a CAGR of over 20%[51]. - The public medical institutions' consumables management market is experiencing stable growth, driven by the need for cost control and the integration of AI and big data technologies[52]. - The global microbiome testing market is projected to grow at a CAGR of 22.5%, reaching over 965 million USD by 2029, driven by increasing health awareness and personalized health management needs[80]. Employee Management and Compensation - The total number of employees in the parent company is 239, while the main subsidiaries employ 1,007, resulting in a total of 1,246 employees[184]. - The company maintains a fair and competitive compensation policy, ensuring alignment with national regulations and market standards[185]. - Employee compensation consists of base salary, performance pay, and benefits, with a strong emphasis on linking pay to performance[186]. - The company has implemented a comprehensive training program to enhance employee skills and core competencies, supporting overall business objectives[187]. - The total remuneration for directors, supervisors, and senior management for the year 2024 is RMB 5.7971 million[156]. Regulatory Compliance and Risks - The company faced multiple regulatory warnings and criticisms from the Shanghai Stock Exchange and Hubei Securities Regulatory Bureau between 2022 and 2024, primarily related to information disclosure violations[161][162][164]. - On March 25, 2024, the company received a notice of investigation from the China Securities Regulatory Commission for suspected violations of information disclosure laws[165]. - The company received regulatory warnings from the Shanghai Stock Exchange due to overdue share repurchases, affecting the former chairman and other executives[166]. - The company was fined a total of 6 million for overdue share repurchases, with individual fines of 6.1 million for the former chairman and 1.3 million for the former general manager[169]. - The company is facing risks from intensified market competition and regulatory changes in the healthcare industry, necessitating adjustments in its business model[140]. Shareholder and Capital Management - The company has a cash dividend policy that aims for a minimum of 30% of the average distributable profit over the last three years to be distributed as cash dividends[189]. - For the fiscal year 2024, the company plans not to distribute cash dividends or convert capital reserves into share capital, pending shareholder approval[190]. - The company has not proposed a cash profit distribution plan despite having positive distributable profits, indicating a focus on reinvestment[191]. - The total amount repurchased and canceled over the last three fiscal years is RMB 171,222,135.75[192]. - The average annual net profit over the last three fiscal years is -RMB 180,138,286.54[192]. Board and Management Changes - The company experienced a change in its board of directors, with independent directors Liu Wei and Zhang Kaihua resigning due to term expiration, and new independent directors Zhang Zhaoguo and Shi Xianwang being elected[157]. - Independent director Yao Jiang submitted his resignation on April 26, 2024, and was replaced by Zhang Zhen, who also took over Yao's roles in the board's strategic and nomination committees[158]. - The fifth board and supervisory board elections were completed in August 2024, with new appointments including Wen Wei as chairman and Wang Zheng as general manager[159].

Financial Performance - The company reported a revenue of CNY 287.43 million for Q1 2025, a decrease of 40.75% compared to CNY 485.12 million in the same period last year[4]. - The net profit attributable to shareholders was a loss of CNY 14.32 million, down from a profit of CNY 3.16 million in the previous year, representing a decline of 553.66%[4]. - The company's cash flow from operating activities was negative CNY 50.63 million, compared to negative CNY 27.15 million in the same period last year[4]. - Total operating revenue for Q1 2025 was ¥287,429,208.68, a decrease of 40.7% compared to ¥485,121,921.87 in Q1 2024[22]. - Net profit for Q1 2025 was a loss of ¥11,765,669.24, compared to a profit of ¥14,336,396.76 in Q1 2024[23]. - Basic and diluted earnings per share for Q1 2025 were both -¥0.07, compared to ¥0.02 in Q1 2024[24]. Assets and Liabilities - The company’s total assets decreased by 19.74% to CNY 2.27 billion from CNY 2.83 billion at the end of the previous year[5]. - Total liabilities decreased to ¥1,330,358,087.98 in Q1 2025 from ¥1,868,026,362.40 in Q1 2024, a reduction of 28.7%[19]. - The total equity attributable to shareholders decreased to ¥920,025,332.15 in Q1 2025 from ¥934,292,086.63 in Q1 2024, a decline of 1.5%[19]. - The total cash and cash equivalents at the end of Q1 2025 were $165.72 million, slightly down from $169.65 million at the end of Q1 2024[28]. Cash Flow - The company’s cash flow statement for Q1 2025 is unaudited, indicating ongoing financial assessments[25]. - In Q1 2025, the cash inflow from operating activities was $355.44 million, a decrease of 37% compared to $565.54 million in Q1 2024[26]. - The net cash outflow from operating activities in Q1 2025 was $50.63 million, worsening from a net outflow of $27.15 million in Q1 2024[27]. - The net cash flow from investing activities in Q1 2025 was $44.30 million, a significant improvement from a net outflow of $3.65 million in Q1 2024[27]. - The cash inflow from financing activities in Q1 2025 was $42.51 million, compared to $38.80 million in Q1 2024, reflecting a 9% increase[28]. - The net cash outflow from financing activities in Q1 2025 was $35.42 million, an improvement from a net outflow of $63.39 million in Q1 2024[28]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 46,600[13]. - The largest shareholder, Saihai (Shanghai) Health Technology Co., Ltd., holds 21,642,540 shares, accounting for 11.33% of total shares[13]. - The top ten shareholders include various institutional and individual investors, with no significant changes in their holdings reported[15]. Research and Development - The company plans to increase R&D investment in smart hospital construction, IoT applications, and big data analysis platforms, which has led to a 43.54% increase in R&D expenses[10]. - The company's R&D expenses increased to ¥13,980,853.82 in Q1 2025, up 43.5% from ¥9,739,943.89 in Q1 2024[22]. - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[15]. Other Financial Metrics - The company reported a non-recurring gain of CNY 14.14 million, primarily from the disposal of non-current assets[8]. - Total expenses (selling, administrative, and financial) were CNY 74.59 million, a reduction of 5.11% compared to the same period last year[6]. - The weighted average return on equity was -1.68%, down from 0.28% in the same period last year, a decrease of 1.96 percentage points[5]. - The company reported an investment income of ¥11,670,780.29 in Q1 2025, compared to a loss of ¥3,391,747.83 in Q1 2024[23].